Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation.

[1]  Yuri Lazebnik,et al.  Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells , 1997, The EMBO journal.

[2]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[3]  R. Craig,et al.  Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. , 1997, Blood.

[4]  K. L. Fries,et al.  Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene , 1996, Journal of virology.

[5]  J. Banchereau,et al.  Epstein‐Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. , 1996, The EMBO journal.

[6]  E. Kieff,et al.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation , 1996, Molecular and cellular biology.

[7]  R. Flavell,et al.  Expansion or Elimination of B Cells In Vivo: Dual Roles for CD40- and Fas (CD95)-Ligands Modulated by the B Cell Antigen Receptor , 1996, Cell.

[8]  I. Weissman,et al.  The c-kit+ maturation pathway in mouse thymic T cell development: lineages and selection. , 1996, Immunity.

[9]  E. Flemington,et al.  The Epstein‐Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin‐dependent kinase inhibitors. , 1996, The EMBO journal.

[10]  C. Goodnow.  Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Finkelman,et al.  bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice , 1996, The Journal of experimental medicine.

[12]  J. Banchereau,et al.  Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts , 1996, The Journal of experimental medicine.

[13]  M. Pawlita,et al.  Epstein‐Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c‐myc gene in Burkitt's lymphoma cells. , 1996, The EMBO journal.

[14]  J. Banchereau,et al.  Fas ligation induces apoptosis of CD40-activated human B lymphocytes , 1995, The Journal of experimental medicine.

[15]  P. Krammer,et al.  CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway , 1995, The Journal of experimental medicine.

[16]  D. Green,et al.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl , 1995, The Journal of experimental medicine.

[17]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[18]  M. Tewari,et al.  Activation of the B-cell Surface Receptor CD40 Induces A20, a Novel Zinc Finger Protein That Inhibits Apoptosis (*) , 1995, The Journal of Biological Chemistry.

[19]  D. Dreyfus,et al.  Epstein-Barr virus replicative gene transcription during de novo infection of human thymocytes: simultaneous early expression of BZLF-1 and its repressor RAZ. , 1995, Virology.

[20]  S. Ju,et al.  Protection against Fas-dependent Thl-mediated apoptosis by antigen receptor engagement in B cells , 1995, Nature.

[21]  R. Craig,et al.  The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2 , 1995, The Journal of cell biology.

[22]  C. Ware,et al.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family , 1995, Cell.

[23]  John Calvin Reed,et al.  Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity , 1995, Cell.

[24]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[25]  D. Mosier,et al.  Differential Epstein-Barr virus gene expression in B-cell subsets recovered from lymphomas in SCID mice after transplantation of human peripheral blood lymphocytes , 1995, Journal of virology.

[26]  E. Kremmer,et al.  B‐cell proliferation and induction of early G1‐regulating proteins by Epstein‐Barr virus mutants conditional for EBNA2. , 1995, The EMBO journal.

[27]  C. O'keefe,et al.  Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. , 1994, Genes & development.

[28]  M. Peter,et al.  The Role of APO‐1‐Mediated Apoptosis in the Immune System , 1994, Immunological reviews.

[29]  John Calvin Reed,et al.  Immunohistochemical analysis of in vivo patterns of Bcl-X expression. , 1994, Cancer research.

[30]  Y. Natkunam,et al.  Simultaneous activation of Ig and Oct-2 synthesis and reduction of surface MHC class II expression by IL-6. , 1994, Journal of immunology.

[31]  Y. Lazebnik,et al.  Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE , 1994, Nature.

[32]  C. Reutelingsperger,et al.  Expression on B Cells Undergoing Apoptosis Annexin V for Flow Cytometric Detection of Phosphatidylserine , 2022 .

[33]  G. Peters,et al.  EBNA‐2 and EBNA‐LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein‐Barr virus. , 1994, The EMBO journal.

[34]  T. Curran,et al.  Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region , 1994, Molecular and cellular biology.

[35]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[36]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Korsmeyer,et al.  Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2 , 1993, Journal of virology.

[38]  S. Shurtleff,et al.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. , 1993, Genes & development.

[39]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Kieff,et al.  Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation , 1993, Journal of virology.

[41]  E. Kremmer,et al.  The Epstein‐Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis‐element of the terminal protein 1 gene promoter. , 1993, The EMBO journal.

[42]  Carol D. Laherty,et al.  The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. , 1992, The Journal of biological chemistry.

[43]  M. Hammarskjöld,et al.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity , 1992, Journal of virology.

[44]  D. Gutsch,et al.  Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter , 1992, Journal of virology.

[45]  C. Rooney,et al.  Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes , 1992, Journal of virology.

[46]  E. Kieff,et al.  Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death , 1991, Cell.

[47]  D. Gutsch,et al.  EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus , 1991, Journal of virology.

[48]  J. Zabriskie,et al.  Marked cell-type-specific differences in glycosylation of human interleukin-6. , 1991, Cytokine.

[49]  J. Strominger,et al.  Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Gwyn T. Williams,et al.  Activation of Epstein–Barr virus latent genes protects human B cells from death by apoptosis , 1991, Nature.

[51]  G. Lenoir,et al.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene , 1991, Journal of virology.

[52]  R. Fåhraeus,et al.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  E. Kieff,et al.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1 , 1990, Journal of virology.

[54]  M. Rowe,et al.  Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein , 1990, Journal of virology.

[55]  H C Hemker,et al.  Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. , 1990, The Journal of biological chemistry.

[56]  E. Kieff,et al.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Hirano,et al.  Interleukin 6 induces secretion of IgG1 by coordinated transcriptional activation and differential mRNA accumulation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[58]  W. Hammerschmidt,et al.  Genetic analysis of immortalizing functions of Epstein–Barr virus in human B lymphocytes , 1989, Nature.

[59]  B. Griffin,et al.  Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. , 1989, The Journal of general virology.

[60]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[61]  C. Rooney,et al.  Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus , 1989, Journal of virology.

[62]  P. L. Deininger,et al.  DNA sequence and expression of the B95-8 Epstein—Barr virus genome , 1984, Nature.

[63]  E. Kieff,et al.  Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies , 1983, Journal of virology.

[64]  D. Franklin,et al.  Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. , 1997, Immunity.

[65]  E. Smeland,et al.  Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. , 1996, Cancer research.

[66]  E. Kieff.  Epstein-Barr virus and its replication , 1996 .

[67]  S. Chen‐Kiang,et al.  Regulation of terminal differentiation of human B-cells by IL-6. , 1995, Current topics in microbiology and immunology.

[68]  S. Cory.  Regulation of lymphocyte survival by the bcl-2 gene family. , 1995, Annual review of immunology.

[69]  J. Banchereau,et al.  The CD40 antigen and its ligand. , 1994, Annual review of immunology.

[70]  N. Cooper,et al.  Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[71]  I. Maclennan,et al.  Distinct short‐lived and long‐lived antibody‐producing cell populations , 1986, European journal of immunology.

[72]  R. Gascoyne,et al.  Short Communication Immunohistochemical Analysis of Mci-1 Protein in Human Tissues Differential Regulation of Mcl- 1 and Bcl-2 Protein Production Suggests a Unique Role for Mcl- 1 in Control of Programmed Cell Death In Vivo , 2007 .